Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) with continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.